LABCORP HOLDINGS INC. (LH) Insider Transactions
Over the last 12 months, 24 LABCORP HOLDINGS INC. (LH) insiders filed 233 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $15.7M in open-market sales. 2% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $15.7MOpen-market sells (1y)
- 24Distinct insiders
- 233Transactions filed
- 2%Under Rule 10b5-1 plan
- 2026-06-08Latest filing
Recent Form 4 Filings Most recent 50 of 233 (1-year window)
Each row is a single Form 4 filing event for LH, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Kyle Kathryn W | EVP, Chief Legal Officer | Sell 10b5-1 | S | $201.1K | 762 | $263.89 |
| 2026-05-11 | Schechter Adam H | President & CEO | Sell 10b5-1 | S | $1.5M | 5,903 | $254.50 |
| 2026-03-27 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sell 10b5-1 | S | $436.1K | 1,633 | $267.05 |
| 2026-03-27 | Meltzer Jonathan C | EVP, Operations | Sell 10b5-1 | S | $224.1K | 839 | $267.05 |
| 2026-03-26 | Schechter Adam H | President & CEO | Grant | A | $0 | 58,470 | $0.00 |
| 2026-03-26 | GRAHAM ANITA Z | EVP, CHRO | Grant | A | $0 | 6,604 | $0.00 |
| 2026-03-26 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Grant | A | $0 | 9,304 | $0.00 |
| 2026-03-26 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Grant | A | $0 | 2,968 | $0.00 |
| 2026-03-26 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Grant | A | $0 | 9,304 | $0.00 |
| 2026-03-26 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Grant | A | $0 | 1,986 | $0.00 |
| 2026-03-26 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | A | $0 | 2,388 | $0.00 |
| 2026-03-26 | Vaughn Bryan T | EVP, Diagnostics | Grant | A | $0 | 1,584 | $0.00 |
| 2026-03-26 | van der Vaart Sandra D | EVP, Corporate Affairs | Grant | A | $0 | 6,382 | $0.00 |
| 2026-03-26 | Summy Amy B. | EVP, Chief Marketing Officer | Grant | A | $0 | 3,994 | $0.00 |
| 2026-03-26 | Oyegunwa Akinbolade | EVP, CIO & CTO | Grant | A | $0 | 1,340 | $0.00 |
| 2026-03-26 | Meltzer Jonathan C | EVP, Operations | Grant | A | $0 | 2,388 | $0.00 |
| 2026-03-26 | Kyle Kathryn W | EVP, Chief Legal Officer | Grant | A | $0 | 1,584 | $0.00 |
| 2026-03-26 | Bailey Megan D. | EVP, Pres, Central Labs & Intl | Grant | A | $0 | 1,184 | $0.00 |
| 2026-03-26 | Schechter Adam H | President & CEO | Other | F | $7.0M | 26,106 | $268.38 |
| 2026-03-26 | GRAHAM ANITA Z | EVP, CHRO | Other | F | $772.7K | 2,879 | $268.38 |
| 2026-03-26 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Other | F | $1.2M | 4,600 | $268.38 |
| 2026-03-26 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Other | F | $394.0K | 1,468 | $268.38 |
| 2026-03-26 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Other | F | $1.1M | 4,042 | $268.38 |
| 2026-03-26 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Other | F | $231.6K | 863 | $268.38 |
| 2026-03-26 | Wilkinson Peter J | SVP, Chief Accounting Officer | Other | F | $202.6K | 755 | $268.38 |
| 2026-03-26 | Vaughn Bryan T | EVP, Diagnostics | Other | F | $121.0K | 451 | $268.38 |
| 2026-03-26 | van der Vaart Sandra D | EVP, Corporate Affairs | Other | F | $730.5K | 2,722 | $268.38 |
| 2026-03-26 | Summy Amy B. | EVP, Chief Marketing Officer | Other | F | $492.7K | 1,836 | $268.38 |
| 2026-03-26 | Oyegunwa Akinbolade | EVP, CIO & CTO | Other | F | $102.5K | 382 | $268.38 |
| 2026-03-26 | Meltzer Jonathan C | EVP, Operations | Other | F | $190.8K | 711 | $268.38 |
| 2026-03-26 | Kyle Kathryn W | EVP, Chief Legal Officer | Other | F | $121.0K | 451 | $268.38 |
| 2026-03-26 | Bailey Megan D. | EVP, Pres, Central Labs & Intl | Other | F | $129.1K | 481 | $268.38 |
| 2026-03-03 | Schechter Adam H | President & CEO | Sell | — | $2.4M | 8,705 | $279.96 |
| 2026-02-27 | van der Vaart Sandra D | EVP, Corporate Affairs | Sell | — | $156.0K | 548 | $284.91 |
| 2026-02-24 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Sell | — | $429.5K | 1,500 | $286.31 |
| 2026-02-19 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sell | — | $185.1K | 666 | $277.94 |
| 2026-02-12 | Meltzer Jonathan C | EVP, Operations | Sell | — | $25.3K | 87 | $290.42 |
| 2026-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | Grant | — | $0 | 230 | — |
| 2026-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | Grant | — | $24.1K | 83 | $289.89 |
| 2026-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | Grant | — | $0 | 230 | $0.00 |
| 2026-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | — | $0 | 536 | — |
| 2026-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | — | $46.4K | 160 | $289.89 |
| 2026-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | — | $0 | 160 | — |
| 2026-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | — | $13.3K | 46 | $289.89 |
| 2026-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | — | $0 | 536 | $0.00 |
| 2026-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | — | $0 | 160 | $0.00 |
| 2026-02-11 | Wang Julia Aijun | Chief Financial Officer, EVP | Grant | — | $0 | 860 | — |
| 2026-02-11 | Wang Julia Aijun | Chief Financial Officer, EVP | Grant | — | $71.0K | 245 | $289.89 |
| 2026-02-11 | Wang Julia Aijun | Chief Financial Officer, EVP | Grant | — | $0 | 860 | $0.00 |
| 2026-02-11 | Vaughn Bryan T | EVP, Diagnostics | Grant | — | $0 | 323 | — |
Showing the most recent 50 of 233 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track LH Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for LABCORP HOLDINGS INC.?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of LABCORP HOLDINGS INC. (LH) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of LABCORP HOLDINGS INC. (LH) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.